Revenue
0 USD
2027 Q1 · USD
Exact inputs and evidence
- Revenue: 0 USD Source
Fundies. English
PHARMACYTE BIOTECH, INC.
EDGARAnnual consolidated revenue for 2026: about USD 0, using the latest reported figures. The previous period, 2025, was about USD 0.
Latest quarter
Operating cash flow
-781 thousand USD
2027 Q1 · USD
Exact inputs and evidence
- Operating Cash Flow: -780894 USD Source
- Cash and cash equivalents
- 17.7 million USD Source
Exact value
17738991 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 10.7 million shares Source
Exact value
10735649 shares
Reported share-count change
57.98% · 3.94 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Revenue
0 USD
2025-08-01 – 2026-07-31
Net income
-16.1 million USD
2025-08-01 – 2026-07-31
Exact inputs and evidence
Operating cash flow
-3.94 million USD
2025-08-01 – 2026-07-31
Exact inputs and evidence
- Operating cash flow: -2973504 USD · 2025-05-01 – 2025-10-31 Source
- Operating cash flow: -1993981 USD · 2025-05-01 – 2025-07-31 Source
- Operating cash flow: -3760352 USD · 2025-05-01 – 2026-01-31 Source
- Operating cash flow: -2973504 USD · 2025-05-01 – 2025-10-31 Source
- Operating cash flow: -5152914 USD · 2025-05-01 – 2026-04-30 Source
- Operating cash flow: -3760352 USD · 2025-05-01 – 2026-01-31 Source
- Operating cash flow: -780894 USD · 2026-05-01 – 2026-07-31 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-16.
Financial data available through: 2026-04-30.
Coverage by financial measure
- Revenue: 11 of 11 periods available· newest 2026-04-30
- Operating income: 11 of 11 periods available· newest 2026-04-30
- Net income: 11 of 11 periods available· newest 2026-04-30
- Operating cash flow: 11 of 11 periods available· newest 2026-04-30
- capital expenditure: No compatible figures in this window
- Total assets: 11 of 11 periods available· newest 2026-04-30
- Total liabilities: 11 of 11 periods available· newest 2026-04-30
- Current assets: 11 of 11 periods available· newest 2026-04-30
- Current liabilities: 11 of 11 periods available· newest 2026-04-30
- Cash and cash equivalents: 5 of 11 periods available· newest 2026-04-30
- long term debt: No compatible figures in this window
- Shares outstanding: 11 of 11 periods available· newest 2026-04-30
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Revenue
USD 0Prior period
USD 0
–
Current period
USD 0
–
Exact inputs and evidence
0 − 0 = 0 USD
0 USD · 2024-05-01 – 2025-04-30
Inspect prior input Prior source0 USD · 2025-05-01 – 2026-04-30
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Net income
-163.4%Prior period
USD 30.66 million
–
Current period
−USD 19.42 million
–
Exact inputs and evidence
-19424654 − 30656050 = -50080704 USD
30656050 USD · 2024-05-01 – 2025-04-30
Inspect prior input Prior source-19424654 USD · 2025-05-01 – 2026-04-30
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 2.17 millionPrior period
−USD 2.98 million
–
Current period
−USD 5.15 million
–
Exact inputs and evidence
-5152914 − -2978296 = -2174618 USD
-2978296 USD · 2024-05-01 – 2025-04-30
Inspect prior input Prior source-5152914 USD · 2025-05-01 – 2026-04-30
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2026 2025-05-01 – 2026-04-30
- Revenue USD 0
- Operating costs Derived USD 6.85 million
- Operating income −USD 6.85 million
- Tax, interest and other Derived USD 12.57 million
- Net income −USD 19.42 million
Cash
- Operating cash flow −USD 5.15 million
- Capital expenditure Unavailable An input is unavailable.
- Free cash flow Derived Unavailable An input is unavailable.
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2017 Not shown: operating income or net income is not reported.
- 2018 Not shown: operating income or net income is not reported.
- 2019 Not shown: operating income or net income is not reported.
- 2020 Not shown: operating income or net income is not reported.
- 2021 Not shown: operating income or net income is not reported.
- 2022 Not shown: operating income or net income is not reported.
- 2023 Not shown: operating income or net income is not reported.
- 2024 Not shown: operating income or net income is not reported.
- 2025 Not shown: operating income or net income is not reported.
- 2026 Not shown: operating income or net income is not reported.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2017 2016-05-01 – 2017-04-30 | 0 | 4442146 Derived | -4442146 | 1539 Derived | -4443685 | Unavailable | Source
|
| 2018 2017-05-01 – 2018-04-30 | 0 | 6981429 Derived | -6981429 | -152588 Derived | -6828841 | Unavailable | Source
|
| 2019 2018-05-01 – 2019-04-30 | 0 | 4100629 Derived | -4100629 | -33401 Derived | -4067228 | Unavailable | Source
|
| 2020 2019-05-01 – 2020-04-30 | 0 | 3826395 Derived | -3826395 | 493 Derived | -3826888 | Unavailable | Source
|
| 2021 2020-05-01 – 2021-04-30 | 0 | 3622981 Derived | -3622981 | -71745 Derived | -3551236 | Unavailable | Source
|
| 2022 2021-05-01 – 2022-04-30 | 0 | 4392014 Derived | -4392014 | -152853 Derived | -4239161 | Unavailable | Source
|
| 2023 2022-05-01 – 2023-04-30 | 0 | 6455494 Derived | -6455494 | -2139501 Derived | -4315993 | Unavailable | Source
|
| 2024 2023-05-01 – 2024-04-30 | 0 | 8520008 Derived | -8520008 | -8853771 Derived | 333763 | Unavailable | Source
|
| 2025 2024-05-01 – 2025-04-30 | 0 | 4377862 Derived | -4377862 | -35033912 Derived | 30656050 | Unavailable | Source
|
| 2026 2025-05-01 – 2026-04-30 | 0 | 6853713 Derived | -6853713 | 12570941 Derived | -19424654 | Unavailable | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 0 2026
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2017 | Revenue | 0 |
|
| 2018 | Revenue | 0 |
|
| 2019 | Revenue | 0 |
|
| 2020 | Revenue | 0 |
|
| 2021 | Revenue | 0 |
|
| 2022 | Revenue | 0 |
|
| 2023 | Revenue | 0 |
|
| 2024 | Revenue | 0 |
|
| 2025 | Revenue | 0 |
|
| 2026 | Revenue | 0 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2017 | Year over year | No prior comparable period |
|
| 2018 | Year over year | No prior comparable period |
|
| 2019 | Year over year | No prior comparable period |
|
| 2020 | Year over year | No prior comparable period |
|
| 2021 | Year over year | No prior comparable period |
|
| 2022 | Year over year | No prior comparable period |
|
| 2023 | Year over year | No prior comparable period |
|
| 2024 | Year over year | No prior comparable period |
|
| 2025 | Year over year | No prior comparable period |
|
| 2026 | Year over year | No prior comparable period |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2017 | Operating margin | Not reported |
|
| 2018 | Operating margin | Not reported |
|
| 2019 | Operating margin | Not reported |
|
| 2020 | Operating margin | Not reported |
|
| 2021 | Operating margin | Not reported |
|
| 2022 | Operating margin | Not reported |
|
| 2023 | Operating margin | Not reported |
|
| 2024 | Operating margin | Not reported |
|
| 2025 | Operating margin | Not reported |
|
| 2026 | Operating margin | Not reported |
|
| 2017 | Net margin | Not reported |
|
| 2018 | Net margin | Not reported |
|
| 2019 | Net margin | Not reported |
|
| 2020 | Net margin | Not reported |
|
| 2021 | Net margin | Not reported |
|
| 2022 | Net margin | Not reported |
|
| 2023 | Net margin | Not reported |
|
| 2024 | Net margin | Not reported |
|
| 2025 | Net margin | Not reported |
|
| 2026 | Net margin | Not reported |
|
| 2017 | Free cash flow margin | Not reported |
|
| 2018 | Free cash flow margin | Not reported |
|
| 2019 | Free cash flow margin | Not reported |
|
| 2020 | Free cash flow margin | Not reported |
|
| 2021 | Free cash flow margin | Not reported |
|
| 2022 | Free cash flow margin | Not reported |
|
| 2023 | Free cash flow margin | Not reported |
|
| 2024 | Free cash flow margin | Not reported |
|
| 2025 | Free cash flow margin | Not reported |
|
| 2026 | Free cash flow margin | Not reported |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD -5.2M 2026
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2017 | Operating cash flow | -3339462 |
|
| 2018 | Operating cash flow | -5079395 |
|
| 2019 | Operating cash flow | -2877912 |
|
| 2020 | Operating cash flow | -2338373 |
|
| 2021 | Operating cash flow | -3330889 |
|
| 2022 | Operating cash flow | -4117319 |
|
| 2023 | Operating cash flow | -3793731 |
|
| 2024 | Operating cash flow | -2151457 |
|
| 2025 | Operating cash flow | -2978296 |
|
| 2026 | Operating cash flow | -5152914 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2017 | Free cash flow | Unavailable |
|
| 2018 | Free cash flow | Unavailable |
|
| 2019 | Free cash flow | Unavailable |
|
| 2020 | Free cash flow | Unavailable |
|
| 2021 | Free cash flow | Unavailable |
|
| 2022 | Free cash flow | Unavailable |
|
| 2023 | Free cash flow | Unavailable |
|
| 2024 | Free cash flow | Unavailable |
|
| 2025 | Free cash flow | Unavailable |
|
| 2026 | Free cash flow | Unavailable |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
25.2% 2026
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2017 | Liabilities / assets | 6.7% |
|
| 2018 | Liabilities / assets | 10% |
|
| 2019 | Liabilities / assets | 12.8% |
|
| 2020 | Liabilities / assets | 17.5% |
|
| 2021 | Liabilities / assets | 9.8% |
|
| 2022 | Liabilities / assets | 0.8% |
|
| 2023 | Liabilities / assets | 0.8% |
|
| 2024 | Liabilities / assets | 34% |
|
| 2025 | Liabilities / assets | 5.9% |
|
| 2026 | Liabilities / assets | 25.2% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
45.28× 2026
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2017 | Current assets / current liabilities | 6.1× |
|
| 2018 | Current assets / current liabilities | 1.99× |
|
| 2019 | Current assets / current liabilities | 0.88× |
|
| 2020 | Current assets / current liabilities | 1.01× |
|
| 2021 | Current assets / current liabilities | 3.14× |
|
| 2022 | Current assets / current liabilities | 121.38× |
|
| 2023 | Current assets / current liabilities | 116.18× |
|
| 2024 | Current assets / current liabilities | 6.8× |
|
| 2025 | Current assets / current liabilities | 7.68× |
|
| 2026 | Current assets / current liabilities | 45.28× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2017 2016-05-01 – 2017-04-30 | −USD 4.44 million Exact valueExact value: -4443685 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 3.34 million Exact valueExact value: -3339462 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2018 2017-05-01 – 2018-04-30 | −USD 6.83 million Exact valueExact value: -6828841 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 5.08 million Exact valueExact value: -5079395 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2019 2018-05-01 – 2019-04-30 | −USD 4.07 million Exact valueExact value: -4067228 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.88 million Exact valueExact value: -2877912 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2020 2019-05-01 – 2020-04-30 | −USD 3.83 million Exact valueExact value: -3826888 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.34 million Exact valueExact value: -2338373 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2021 2020-05-01 – 2021-04-30 | −USD 3.55 million Exact valueExact value: -3551236 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 3.33 million Exact valueExact value: -3330889 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2022 2021-05-01 – 2022-04-30 | −USD 4.24 million Exact valueExact value: -4239161 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 4.12 million Exact valueExact value: -4117319 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2022-05-01 – 2023-04-30 | −USD 4.32 million Exact valueExact value: -4315993 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 3.79 million Exact valueExact value: -3793731 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2023-05-01 – 2024-04-30 | USD 333,763 Exact valueExact value: 333763 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.15 million Exact valueExact value: -2151457 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2024-05-01 – 2025-04-30 | USD 30.66 million Exact valueExact value: 30656050 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.98 million Exact valueExact value: -2978296 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2026 2025-05-01 – 2026-04-30 | −USD 19.42 million Exact valueExact value: -19424654 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 5.15 million Exact valueExact value: -5152914 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
129 filings · 3,409 latest values · 3,409 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001157075, 1157075, PMCB, edgar:1157075
Also known as EFOODSAFETY COM INC, NUVILEX, INC., Nuvilex, Inc., PHARMACYTE BIOTECH, INC., PharmaCyte Biotech, Inc.